Xience Prime Coronary Stent Offers Greater Flexibility


November 2, 2011

The Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease uses the same drug and biocompatible polymer as the Xience V, but features an enhanced stent design and a delivery system designed for greater flexibility, better radial strength, longitudinal strength and more accurate stent placement.

Xience Prime is based on the stent design of the Multi-Link family. It utilizes cobalt chromium technology and features a "peak-to-valley" mechanical design that imparts longitudinal strength and stability to the stent. To date, the stents based on the Multi-Link design – including Vision, Xience V, Promus and Xience Prime – represent more than 300 million implant months, which is a measure of the clinical experience that supports this stent design. In addition, Xience Prime features one of the thinnest DES struts available while maintaining radial strength to support the vessel, and it provides excellent visibility under X-ray during stent implantation procedures. The stent is offered in long lengths up to 38 mm.

FDA approval was supported by results from the SPIRIT PRIME clinical trial, a prospective, open-label trial that evaluated Xience Prime in 500 patients with coronary artery disease. The trial met its primary endpoint, with low rates of target lesion failure (TLF) at one year.

Xience Prime received CE mark in 2009. The U.S. Food and Drug Administration (FDA) granted market clearance in November 2011.

For more information: www.abbott.com